Last updated: May 26, 2026
Carbidopa, Entacapone & Levodopa Supplier Landscape: Who Makes API and Key Intermediates Used in COMT/Levodopa Combination Products
Carbidopa, entacapone, and levodopa are supplied through a mature global API supply base dominated by specialized small-molecule manufacturers. Most branded “triple” and “dual” regimens rely on outsourced API and intermediates, with formulation and packaging performed by downstream licensees under separate commercial contracts. The practical supplier set for R&D and commercial manufacturing is split into (1) API and critical intermediate manufacturers for carbidopa/entacapone/levodopa and (2) finished-dose and packaging suppliers that convert APIs into tablet strengths and maintain regulatory dossiers.
What companies supply carbidopa API and carbidopa intermediate starting materials?
Carbidopa (CAS 154-06-1) is produced from established chiral and heterocycle routes using precursors such as substituted hydrazines/aryl acids and protecting group chemistry. Supplier identification in this segment is typically via DMF-holder networks and contract manufacturing relationships, with multiple vendors in China, India, and Europe.
Common API supply positions
- DMF or API dossier suppliers: API manufacturers that hold regulatory submissions for carbidopa.
- Intermediate suppliers: firms supplying carbidopa precursors (often the stereochemical or substituted aryl building blocks) to API makers.
- Finished-dose contractors: tablet manufacturers that buy carbidopa API (or carbidopa blends) and perform compression, coating, and packaging.
Commercially relevant sourcing constraints
- Chirality control for carbidopa-related intermediates.
- Impurity profile alignment with regulatory acceptance criteria.
- Scalability of batch crystallization/solvent recovery given carbidopa’s typical isolation steps.
Which suppliers make entacapone API and entacapone intermediates for COMT inhibitor tablets?
Entacapone (CAS 13010-48-3) is a COMT inhibitor commonly used in combination with levodopa. API supply relies on multi-step heteroaryl synthesis with key intermediates involving nitro/halogen substitutions and later cyclization or coupling steps.
API and intermediate procurement pattern
- API purchase through DMF-linked manufacturers: typical for downstream licensees.
- Intermediate supply is more common than direct levelling of synthesis routes: many commercial buyers source advanced intermediates from specialized vendors and let API manufacturers complete the final synthesis and crystallization.
Quality and regulatory focus
- Specified genotoxic impurity controls (process-dependent).
- Polymorph and crystallization control to meet dissolution and impurity targets.
- Consistent residue solvents based on solvent class used in purification.
Who supplies levodopa API for Parkinson’s disease formulations?
Levodopa (CAS 59-92-7) is produced via catechol-derived and protected amino acid or direct substitution routes depending on vendor capability. Its supply base is broad, with suppliers serving both direct API markets and intermediate-to-API contracts.
Typical supply chain structure
- API manufacturers produce levodopa in powder form for tablet makers.
- Intermediate suppliers provide protected catechol/amino precursors used to reduce cost or lead time.
- Downstream formulation sites manage blending, compression, and coating under controlled impurity specifications.
Key commercial differentiators
- Impurity breadth tied to oxidation and polymerization risk of catechol moieties.
- Stability controls during storage and blending.
- Consistency in particle size distribution for tablet uniformity and dissolution.
How do API supplier networks differ for “triple therapy” vs “dual therapy” (carbidopa/levodopa plus entacapone)?
Most markets treat these as two product families:
- Carbidopa/levodopa (dopamine precursor + decarboxylase inhibitor) tablets.
- Levodopa/carbidopa + entacapone (COMT inhibitor add-on) tablets.
Implication for sourcing
- A carbidopa/levodopa tablet supply contract often uses the same API suppliers year to year.
- Entacapone introduces an extra API stream with a different impurity pattern and different crystallization behaviors, which can force qualification of a new entacapone supplier even when levodopa and carbidopa sources remain unchanged.
What finished-dose CDMO suppliers manufacture carbidopa/levodopa and entacapone tablets?
Finished-dose manufacturers do the final dosage form. Their supplier role is distinct from API makers and is usually governed by:
- approved regulatory filings,
- quality agreements,
- and site-specific equipment validation for granulation, blending, compression, and coating.
Downstream manufacturing typical scope
- tablet core compression and film coating,
- packaging (bottles, blister lines),
- batch release testing under cGMP.
Commercial due diligence lens
- ability to meet dissolution spec across strengths,
- control over cross-contamination and cleaning validation,
- and supply assurance for combination therapy SKUs.
What are the most common buying models: direct API purchase, DMF reliance, or licensed formulation?
Pharma procurement uses three common models:
-
Direct API procurement
- Buyer qualifies API suppliers under its own quality systems.
- Often used for new entrants and scale-up phases.
-
DMF-reliant procurement
- Buyer leverages supplier regulatory filings to reduce submission burden.
- Typical when time-to-market matters.
-
Licensed formulation or contract manufacturing
- Buyer licenses a dosage-form technology and contracts with a tablet/CDMO.
- Common when the buyer has API supply but needs regulatory and commercial manufacturing capacity.
Which supplier countries dominate carbidopa, entacapone, and levodopa API production?
Supply is heavily concentrated in established manufacturing hubs:
- India and China dominate volume and cost competitiveness for small-molecule API and many intermediate tiers.
- Europe has a smaller number of players focused on specialty quality systems and dossiers, plus supply for certain regulated markets.
Procurement implication
- For businesses managing risk (supply continuity, quality deviations, or regulatory change control), the practical approach is multi-sourcing with at least two qualified API streams per actives.
How do you qualify a new carbidopa/entacapone/levodopa supplier for regulatory-grade supply?
Qualification usually includes:
- vendor and site audit (quality management, deviations, CAPA systems),
- comparability protocol if changing API source for an existing commercial product,
- analytical method bridging for impurity and dissolution alignment,
- stability testing of the API and the formulated product (often accelerated and long-term),
- residual solvents and elemental impurity checks aligned to relevant pharmacopeial and ICH expectations.
What patent and IP risks affect supplier switching for carbidopa/levodopa/entacapone products?
At the supplier level, IP risk typically sits in:
- process patents (manufacturing routes),
- polymorph/crystal form patents (for certain APIs),
- and formulation patents (combination tablets, coatings, release profiles).
For a supplier switch, the risk is not that API makers infringe on “stock” patents in every case, but that:
- the commercial product’s dossier is tied to a specific impurity profile and manufacturing route, and
- a change could require bridging studies and possible licensing if an active patent remains in force.
Key Takeaways
- Carbidopa, entacapone, and levodopa are supplied by a well-established global API ecosystem, with procurement commonly split between API/critical intermediate suppliers and downstream tablet CDMOs.
- Switching supply for combination therapy usually requires qualification of entacapone separately from carbidopa/levodopa due to impurity and crystallization differences.
- Qualification is process-and-impurity driven: regulatory-grade supply hinges on bridging analytics, stability, and dossier alignment.
- IP risk for supplier switching is most often tied to process and formulation IP linked to the commercial product’s regulatory filings.
FAQs
- Do carbidopa/levodopa combination tablet manufacturers source from the same API suppliers as entacapone add-on tablets?
- What impurity classes are most frequently monitored for levodopa and entacapone API quality during supplier qualification?
- How long does it typically take to qualify a new entacapone API supplier under cGMP and regulatory bridging requirements?
- Can a company rely on a supplier’s DMF for carbidopa or entacapone procurement without changing its own analytical release testing?
- What manufacturing steps are most sensitive to failure modes when scaling levodopa or entacapone synthesis and purification?
References
- ICH. “ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.” International Council for Harmonisation, 2000.
- ICH. “ICH Q3A(R2): Impurities in New Drug Substances.” International Council for Harmonisation.
- ICH. “ICH Q3B(R2): Impurities in New Drug Products.” International Council for Harmonisation.
